$80.00
Tesamorelin Structure
Sequence (Single Letter): Unk-Tyr-Ala-Asp-Ala-lle-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-lle-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu
Molecular Formula: C223H370N72O69S
Molecular Weight: 5195.908 g/mol
PubChem CID: 44147413
CAS Number: 901758-09-6
Tesamorelin, an analogue of growth hormone releasing hormone (GHRH), mirrors the structure of standard GHRH, enhanced by the addition of an extra trans-3-hexanoic acid group. Developed by Theratechnologies in Canada, Tesamorelin earned FDA approval in 2010 as the latest drug for managing HIV-associated lipodystrophy. Beyond its approved use, the peptide has undergone exploration regarding its potential to enhance peripheral nerve regeneration and as a potential intervention for mild cognitive impairment (MCI), which precedes dementia.
